|
EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Clinical research trials and EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer. EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer clinical trial. Test subjects oftentimes recieve the best healthcare possible for their EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer  EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
For Condition: Ovarian Neoplasms,Peritoneal Neoplasms,Fallopian Tube Neoplasms
Status: Suspended
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause ovarian, fallopian, or peritoneal cancers.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Female
Protocol Entry Criteria: Inclusion Criteria The following patients may be eligible for the study: - Histologically or cytologically documented evidence of ovarian, primary Fallopian or primary peritoneal cancer with at least one measurable lesion (if previous radiation treatment, the target lesion must have demonstrated progression since the radiation) - Must have a life expectancy of greater than three (3) months - Prior failure to respond following front-line treatment with a taxane and platinum (or a combination therapy) may be eligible. Exclusion Criteria The following patients are not eligible for the study: - Patients with radiation therapy or chemotherapy within the last four weeks - Patients who have had any chemotherapy not containing a taxane and platinum for their disease - Patients with borderline ovarian and macropapillary tumors - Patients with unresolved bowel obstruction - Patients with symptomatic CNS metastases or leptomeningeal involvement - Patients with any peripheral neuropathy or unresolved diarrhea greater than Grade 1 - Patients with severe cardiac insufficiency - Patients taking Coumadin or other warfarin-containing agents with the exception of low dose Coumadin (1 mg or less) for the maintenance of in-dwelling lines or ports - History of another malignancy within 5 years prior to study entry except curatively treated non-melanoma skin cancer or cervical cancer in situ - Patients with active or suspected acute or chronic uncontrolled infection including abcesses or fistulae - HIV+ patients - Pregnant or lactating females.
Total Enrollment: 48
Location and Contact Information:
Cancer Institute of New Jersey (CINJ)
New Brunswick, New Jersey, 08901
United States
Additional Information:
Study ID Numbers: CEPO906A-2203;
Study Start Date:
Record last reviewed: December 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035100
Other Ovarian Neoplasms Studies:
1. Phase II Study in Patients with EGFR + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
2. EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Related Studies:
Other Ovarian Neoplasms Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials
EPO906 Therapy in Patients with Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
|
|
|
|
|
|
|
|
